肿瘤细胞治疗研究
英文原题：Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia.
迄今为止，细胞疗法在急性髓系白血病（AML）中显示出的疗效有限。
迄今为止，细胞疗法在急性髓系白血病（AML）中显示出有限的疗效。一项近期研究表明，mTOR复合物1激活下调CXCR4，从而减少靶向EpCAM的嵌合抗原受体（CAR）T细胞在AML中的骨髓浸润。在IL2介导的体外扩增过程中，通过联合使用mTOR抑制剂阻断mTOR信号通路，可上调CXCR4，并增强CAR T细胞的骨髓迁移及对AML的清除能力。参见Nian等人发表于第6026页的相关文章。
Cellular therapies have demonstrated limited efficacy thus far in acute myeloid leukemia (AML). A recent study shows that mTOR complex 1 activation downregulated CXCR4 reducing marrow infiltration of EpCAM-targeting chimeric antigen receptor (CAR) T-cells in AML. Abrogating mTOR signaling by cotreatment with mTOR inhibitors during IL2-mediated ex vivo expansion upregulated CXCR4 and bolstered bone marrow migration and AML elimination by CAR T-cells. See related article by Nian et al., p. 6026 .
MEMBER ACCOUNT
登录成功会直接打开下一页。
